paroxetine has been researched along with Alzheimer Disease in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Finsen, B; Gramsbergen, JB; Hasselstrøm, J; Lambertsen, KL; Metaxas, A; Olesen, LØ; Severino, M; Sivasaravanaparan, M; von Linstow, CU; Wiborg, O | 1 |
| Ai, PH; Chen, S; Feng, DF; Liu, XD; Pan, YB; Sun, S; Xu, NJ; Zhu, XN | 1 |
| Baroni, M; Boccardi, V; Ercolani, S; Giordano, M; Longo, A; Mecocci, P; Paolacci, L; Ruggiero, C | 1 |
| Bouzinova, EV; Finsen, B; Hasselstrøm, JB; Olesen, LØ; Severino, M; Sivasaravanaparan, M; Wiborg, O | 1 |
| Alexopoulos, GS | 1 |
| Ellison, JM | 1 |
| Bertoletti, E; Chilovi, BV; Conti, M; Padovani, A; Rozzini, L; Trabucchi, M; Zanetti, M | 1 |
| Collins, A; Gragg, M; Sherrod, RA; Wynn, S | 1 |
| Fang, Y; Jia, Y; Lian, Y; Wei, J; Xu, Y; Zeng, Z; Zhang, L; Zhao, X; Zhu, H | 1 |
| Lebert, F | 1 |
| Cahill, CM; Gullans, SR; Payton, S; Randall, JD; Rogers, JT | 1 |
| Cuny, GD; Morse, LJ; Payton, SM; Rogers, JT | 1 |
| Ahl, M; Bush, A; Huang, X; Rogers, JT; Tucker, S; Westaway, D | 1 |
| Ahl, M; Bandyopadhyay, S; Bush, AI; Cho, HH; Cuny, GD; Goldstein, LE; Huang, X; Rogers, JT; Tucker, S; Westaway, D | 1 |
| Brown, M; Clark, RF; Gray, AJ; Guo, Z; Halagappa, VM; Iyun, T; Martin, B; Matsuoka, Y; Mattson, MP; Maudsley, S; Nelson, RL; Pearson, M | 1 |
| Bales, KR | 1 |
| Reynolds, CF | 1 |
| Burke, WJ; Dewan, V; Folks, DG; Nadolny, GC; Roccaforte, WH; Wengel, SP | 1 |
| Cohen, CI; Trappler, B | 1 |
| Bensasi, S; Houck, PR; Mazumdar, S; Miller, MD; Mulsant, BH; Nebes, R; Pollock, BG; Reynolds, CF; Stack, J; Sweet, RA | 1 |
3 review(s) available for paroxetine and Alzheimer Disease
| Article | Year |
|---|---|
[Serotonin reuptake inhibitors in depression of Alzheimer's disease and other dementias].
Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Dementia; Depression; Fluoxetine; Humans; Neuropsychological Tests; Paroxetine; Placebos; Selective Serotonin Reuptake Inhibitors; Time Factors; Trazodone | 2003 |
Paroxetine administration decreases AD-like pathology and reverses memory impairments in a transgenic model of Alzheimer disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Memory; Memory Disorders; Mice; Paroxetine | 2007 |
Depression: making the diagnosis and using SSRIs in the older patient.
Topics: 1-Naphthylamine; Adult; Aged; Alzheimer Disease; Depressive Disorder; Diagnosis, Differential; Dose-Response Relationship, Drug; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
2 trial(s) available for paroxetine and Alzheimer Disease
| Article | Year |
|---|---|
Use of SSRIs in "very old" depressed nursing home residents.
Topics: 1-Naphthylamine; Aged; Aged, 80 and over; Alzheimer Disease; Central Nervous System Diseases; Dementia, Vascular; Depressive Disorder; Female; Fluoxetine; Homes for the Aged; Humans; Male; Matched-Pair Analysis; New York; Nursing Homes; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Statistics, Nonparametric | 1998 |
A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients.
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Tricyclic; Depression; Double-Blind Method; Female; Humans; Male; Nortriptyline; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2001 |
15 other study(ies) available for paroxetine and Alzheimer Disease
| Article | Year |
|---|---|
Efficacy of Chronic Paroxetine Treatment in Mitigating Amyloid Pathology and Microgliosis in APPSWE/PS1ΔE9 Transgenic Mice.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloidosis; Animals; Disease Models, Animal; Humans; Mice; Mice, Transgenic; Paroxetine; Plaque, Amyloid; Presenilin-1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins | 2022 |
Paroxetine ameliorates prodromal emotional dysfunction and late-onset memory deficit in Alzheimer's disease mice.
Topics: Affective Symptoms; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Memory Disorders; Mice; Mice, Transgenic; Neuroprotective Agents; Paroxetine; Presenilin-1; Prodromal Symptoms; Receptors, N-Methyl-D-Aspartate; Selective Serotonin Reuptake Inhibitors; Time Factors | 2020 |
Anticholinergic Burden and Functional Status in Older People with Cognitive Impairment: Results from the Regal Project.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinergic Antagonists; Cognitive Dysfunction; Cross-Sectional Studies; Female; Hospitalization; Humans; Italy; Longitudinal Studies; Male; Memory; Outpatients; Paroxetine; Risperidone; Trazodone | 2017 |
Behavioural Phenotyping of APPswe/PS1δE9 Mice: Age-Rrelated Changes and Effect of Long-Term Paroxetine Treatment.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorders; Disease Models, Animal; Male; Maze Learning; Memory Disorders; Mice; Mice, Transgenic; Paroxetine; Presenilin-1; Social Behavior | 2016 |
Personalizing the care of geriatric depression.
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Tricyclic; Brain; Case Management; Comorbidity; Depressive Disorder, Major; Health Services for the Aged; Humans; Magnetic Resonance Imaging; Nortriptyline; Paroxetine; Patient-Centered Care; Psychology; Selective Serotonin Reuptake Inhibitors; Socioeconomic Factors | 2008 |
A 60-year-old woman with mild memory impairment: review of mild cognitive impairment.
Topics: Aging; Alzheimer Disease; Cognition; Cognition Disorders; Counseling; Diagnosis, Differential; Diet; Female; Humans; Life Style; Magnetic Resonance Imaging; Memory Disorders; Middle Aged; Neurotransmitter Agents; Paroxetine; Positron-Emission Tomography; Psychotropic Drugs; Risk Factors | 2008 |
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Citalopram; Cognition; Cognition Disorders; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Movement Disorders; Neuropsychological Tests; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2010 |
Dissecting dementia, depression, and drug effects in older adults.
Topics: Aged; Alzheimer Disease; Antidepressive Agents; Depressive Disorder; Diagnosis, Differential; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Nootropic Agents; Nursing Diagnosis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Substance Withdrawal Syndrome | 2010 |
BDNF gene polymorphisms are associated with Alzheimer's disease-related depression and antidepressant response.
Topics: Aged; Alleles; Alzheimer Disease; Antidepressive Agents; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Depression; Female; Genotype; Humans; Linkage Disequilibrium; Male; Paroxetine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: the action of paroxetine and dimercaptopropanol.
Topics: 5' Untranslated Regions; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Anti-Bacterial Agents; Azithromycin; Cell Line, Tumor; Chelating Agents; Dimercaprol; Drug Evaluation, Preclinical; Genes, Reporter; Humans; Luciferases; Paroxetine; Protein Synthesis Inhibitors; RNA, Messenger; Selective Serotonin Reuptake Inhibitors | 2003 |
FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein.
Topics: 5' Untranslated Regions; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cell Line, Tumor; Chelating Agents; Dimercaprol; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Epithelial Cells; Humans; Iron; Neuroprotective Agents; Organometallic Compounds; Paroxetine; Protein Biosynthesis; Protein Processing, Post-Translational; Protein Synthesis Inhibitors; Receptors, Transferrin; RNA, Messenger | 2004 |
Pilot study of the reducing effect on amyloidosis in vivo by three FDA pre-approved drugs via the Alzheimer's APP 5' untranslated region.
Topics: 5' Untranslated Regions; Acetylcysteine; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Drug Approval; Drugs, Investigational; Erythromycin; Mice; Mice, Transgenic; Paroxetine; Pilot Projects | 2005 |
RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine.
Topics: 5' Untranslated Regions; Acetylcysteine; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Drug Evaluation, Preclinical; Drugs, Investigational; Erythromycin; Mice; Mice, Transgenic; Paroxetine; Peptide Fragments; Pilot Projects; Protein Biosynthesis; Protein Synthesis Inhibitors; RNA, Messenger | 2006 |
Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice.
Topics: Alzheimer Disease; Amygdala; Amyloid beta-Peptides; Animals; Avoidance Learning; Behavior, Animal; Cerebral Cortex; Disease Models, Animal; Female; Hippocampus; Male; Maze Learning; Mental Disorders; Mice; Mice, Transgenic; Motor Activity; Paroxetine; Peptide Fragments; Selective Serotonin Reuptake Inhibitors; Swimming; Tauopathies | 2007 |
The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia.
Topics: 1-Naphthylamine; Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Depressive Disorder; Female; Humans; Male; Paroxetine; Psychotic Disorders; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 1997 |